[1] Seto WK, Liu K,Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol, 2013, 59: 709-716.
[2] Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology, 2013, 58: 325-336.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华肝脏病杂志,2011,19:13-24.
[4] Lee YB, Jung EU, Kim BH, et al. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother, 2015, 59: 972-978.
[5] Jiang YF, He B, Ma J, et al. Comparison of the antiviral effects of entecavir and adefovir dipivoxil in chronic HBV infection: a randomized control trial. Acta gastroenterol Belg, 2012, 75: 316-321.
[6] Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol, 2014, 29: 1139-1148.
[7] Lv GC, Yao JM, Yang YD, et al. Efficacy of combined therapy in with hepatitis B vieus-related decompensated cirrhosis. World J Gastroenterology, 2013,19: 3481 -3486.
[8] Sharma BC,Singh J. Probiotics in management of hepatic cephalopathy. Metab Brain Dis,2016,31:1295-1301.
[9] Ma YJ, He M, Han JA, et al. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand J Immunol, 2013, 78: 387-393.
[10] Li Y,Mei L, Qiang J, et al. Magnetic resonance spectroscopy for evaluating portal-systemic encephalopathy in patients with chronic hepatic schistosomiasis japonicum. PLoS Negl Trop Dis, 2016, 10: e0005232. |
